Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $295835.0.

  • Axsome Therapeutics' Gains from Sales and Divestitures rose 1948.34% to $295835.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $295835.0, marking a year-over-year increase of 1948.34%. This contributed to the annual value of $267779.0 for FY2024, which is 3772.87% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Gains from Sales and Divestitures stood at $295835.0, which was up 1948.34% from $268394.0 recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Gains from Sales and Divestitures ranged from a high of $295835.0 in Q3 2025 and a low of $61581.0 during Q1 2022
  • Its 4-year average for Gains from Sales and Divestitures is $181884.0, with a median of $194425.0 in 2023.
  • In the last 5 years, Axsome Therapeutics' Gains from Sales and Divestitures soared by 16114.95% in 2023 and then skyrocketed by 1606.2% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Gains from Sales and Divestitures stood at $81639.0 in 2022, then soared by 138.15% to $194425.0 in 2023, then surged by 37.73% to $267779.0 in 2024, then rose by 10.48% to $295835.0 in 2025.
  • Its last three reported values are $295835.0 in Q3 2025, $268394.0 for Q2 2025, and $244299.0 during Q1 2025.